A Phase 3 interventional study of Evolocumab and Low-density Lipoprotein Cholesterol (LDL-C) Apheresis in Hypercholesterolemia, sponsored by Amgen. Completed at 17 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-30.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 32nd largest by enrollment, is the only one that started in 2015, is one of 22 in phase 3, and was the 24th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 30th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2015, is one of 22 in phase 3, and was the 24th registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future apheresis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
Biological: Evolocumab
Participants continued apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
Biological: Evolocumab · Procedure: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
Administered by subcutaneous injection once every 2 weeks
Also known as: Repatha, AMG 145
Participants received apheresis for LDL-C according the their physician's prescription and local custom.
Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy
Avoidance of apheresis at end of randomized therapy was defined as no apheresis at week 5 and week 6. Aperesis at weeks 5 or 6 was based on LDL-C level at week 4: participants with LDL-C ≥ 100 mg/dL at week 4 received apheresis at week 5 (participants who received apheresis QW before study entry) or week 6 (participants who received apheresis Q2W prior to study entry). If LDL-C was \< 100 mg/dL at week 4, no apheresis was performed at week 5 or week 6, irrespective of assigned treatment group. Participants who ended the study prior to week 6 were considered as not achieving apheresis avoidance.
Time frame: Week 5 and week 6
Percent Change From Baseline in Low-density Lipoprotein Cholesterol
Time frame: Baseline and week 4
Percent Change From Baseline in Non-high-density Lipoprotein-Cholesterol
Time frame: Baseline and Week 4
Percent Change From Baseline in Total Cholesterol/High-density Lipoprotein Cholesterol Ratio
Time frame: Baseline and Week 4
This study was conducted at 15 centers in the following 8 countries: Australia, Czech Republic, France, Germany, Italy, Spain, the United Kingdom, and the United States. Participants were enrolled from 21 December 2015 to 21 July 2016.
| Milestone | Apheresis | Evolocumab |
|---|---|---|
| Started | 20 | 19 |
| Completed | 20 | 19 |
| Not completed | 0 | 0 |
| Milestone | Apheresis | Evolocumab |
|---|---|---|
| Started | 20 | 19 |
| Completed | 20 | 19 |
| Not completed | 0 | 0 |
Avoidance of apheresis at end of randomized therapy was defined as no apheresis at week 5 and week 6. Aperesis at weeks 5 or 6 was based on LDL-C level at week 4: participants with LDL-C ≥ 100 mg/dL at week 4 received apheresis at week 5 (participants who received apheresis QW before study entry) or week 6 (participants who received apheresis Q2W prior to study entry). If LDL-C was \< 100 mg/dL at week 4, no apheresis was performed at week 5 or week 6, irrespective of assigned treatment group. Participants who ended the study prior to week 6 were considered as not achieving apheresis avoidance.
| percentage of participants | Apheresis | Evolocumab |
|---|---|---|
| Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy | 10.0 (2.8 to 30.1) | 84.2 (62.4 to 94.5) |
| percent change | Apheresis | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein Cholesterol | 2.61 ± 3.97 | -50.13 ± 4.03 |
| percent change | Apheresis | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Non-high-density Lipoprotein-Cholesterol | 1.80 ± 3.29 | -44.58 ± 3.34 |
| percent change | Apheresis | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol/High-density Lipoprotein Cholesterol Ratio | 0.15 ± 2.65 | -35.65 ± 2.67 |
Collected over 6 weeks during the primary period and 20 weeks during the post-primary period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Primary Period: Apheresis QW | — | 0/4 (0%) | 2/4 (50%) |
| Primary Period: Apheresis Q2W | — | 2/16 (12.5%) | 5/16 (31.3%) |
| Primary Period: Evolocumab | — | 0/19 (0%) | 10/19 (52.6%) |
| Post-primary Period: Apheresis/Evolocumab | — | 0/20 (0%) | 6/20 (30%) |
| Post-primary Period: Evolocumab/Evolocumab | — | 2/19 (10.5%) | 8/19 (42.1%) |
| Event | Primary Period: Apheresis QW | Primary Period: Apheresis Q2W | Primary Period: Evolocumab | Post-primary Period: Apheresis/Evolocumab | Post-primary Period: Evolocumab/Evolocumab |
|---|---|---|---|---|---|
| Myocardial ischaemiaCardiac disorders | 0/4 | 1/16 | 0/19 | 0/20 | 0/19 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/4 | 1/16 | 0/19 | 0/20 | 0/19 |
| Retinal vein occlusionEye disorders | 0/4 | 0/16 | 0/19 | 0/20 | 1/19 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/4 | 0/16 | 0/19 | 0/20 | 1/19 |
| Event | Primary Period: Apheresis QW | Primary Period: Apheresis Q2W | Primary Period: Evolocumab | Post-primary Period: Apheresis/Evolocumab | Post-primary Period: Evolocumab/Evolocumab |
|---|---|---|---|---|---|
| Tooth abscessInfections and infestations | 1/4 | 0/16 | 0/19 | 1/20 | 0/19 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/4 | 0/16 | 0/19 | 0/20 | 0/19 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/4 | 1/16 | 2/19 | 1/20 | 0/19 |
| HeadacheNervous system disorders | 0/4 | 0/16 | 2/19 | 2/20 | 1/19 |
| RashSkin and subcutaneous tissue disorders | 0/4 | 0/16 | 2/19 | 0/20 | 1/19 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/16 | 0/19 | 2/20 | 1/19 |
| NauseaGastrointestinal disorders | 0/4 | 0/16 | 0/19 | 2/20 | 0/19 |
| FatigueGeneral disorders | 0/4 | 0/16 | 1/19 | 2/20 | 0/19 |
| Influenza like illnessGeneral disorders | 0/4 | 0/16 | 0/19 | 2/20 | 0/19 |
| Myocardial ischaemiaCardiac disorders | 0/4 | 1/16 | 0/19 | 0/20 | 0/19 |
| Age, Continuous(years) | Apheresis | Evolocumab | Total |
|---|---|---|---|
| Mean | 59.6 ± 10.0 | 65.4 ± 8.1 | 62.4 ± 9.5 |
| Age, Customized(participants) | Apheresis | Evolocumab | Total |
|---|---|---|---|
| < 65 years | 14 | 7 | 21 |
| ≥ 65 years | 6 | 12 | 18 |
| Sex: Female, Male(Participants) | Apheresis | Evolocumab | Total |
|---|---|---|---|
| Female | 7 | 9 | 16 |
| Male | 13 | 10 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Apheresis | Evolocumab | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 20 | 17 | 37 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Apheresis | Evolocumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 20 | 18 | 38 |
| Stratification Factor: Screening LDL-C Level(participants) | Apheresis | Evolocumab | Total |
|---|---|---|---|
| < 160 mg/dL | 11 | 11 | 22 |
| ≥ 160 mg/dL | 9 | 8 | 17 |
| LDL-C Concentration(mg/dL) | Apheresis | Evolocumab | Total |
|---|---|---|---|
| Mean | 150.6 ± 25.6 | 152.4 ± 21.2 | 151.5 ± 23.3 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Dec 2015 to primary completion in Sep 2016, 8 months.
Results were first posted in Sep 2017, 1 year after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 8 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab